Diego Rey
Founder of ENDPOINT HEALTH
San Francisco, California
Overview
Work Experience
Angel investing
2018 - Current
Early stage healthcare, therapeutics, diagnostics, and life sciences investing
Co-Founder & Chief Scientific Officer
2018 - 2024
Endpoint Health develops therapeutics for immune-mediated diseases including RA, IBD, Vasculitides, as well as Sepsis, and ARDS. Endpoint’s key premise is that biological heterogeneity in these diseases limits efficacy potential and addresses this problem by developing blood-based transcriptomic tests (RNA seq and RT-qPCR) to stratify patients based on immune state to then better align therapy pharmacology to patient biology. Therapeutics in development by Endpoint span first-in-class preclinical through repositioning of approved molecules and include monoclonal antibodies, recombinant proteins, and plasma-derived blood products.
Endpoint Health is a precision immunology company
Raised $64,000,000.00 from Global Health Investment Fund (GHIF), Wireframe Ventures, Boom Capital Ventures, Mayfield Fund, The Venture Collective, HCX Ventures, Humboldt Fund, Yaya Capital, Growth Capital Ventures and Alix Ventures.
Expert/Part time Partner
2018 - 2021
Visiting Partner
2017 - 2018
Diego was the first Visiting Partner at Y Combinator focused on life sciences and healthcare companies, where he helped founders build their companies developing diagnostics, therapeutics, medical devices, tools, health IT, and industrial biology products. YC has invested in over a thousand founders who have started 5,000+ companies with a combined value of over $600B and that have created tens of thousands of jobs.
Head of Research, GeneWEAVE Division of Roche Molecular Systems
2015 - 2017
Roche Molecular Systems, Inc., a molecular diagnostics company, develops and commercializes diagnostic and blood screening tests based on
Co-Founder & Chief Technology Officer
2010 - 2015
GeneWEAVE developed tests to get the right antibiotic to patients quickly: in vitro diagnostics for the rapid detection and identification of live bacteria directly from patient specimens and phenotypic determination of antibiotic susceptibility. GeneWEAVE was acquired by Roche and the system and first test for MRSA screening received a De Novo Grant from the FDA. Diego invented the core technology and is the author of 27 issued patents covering the product.
Graduate Research Assistant
2004 - 2010
The Batt Lab is led by Liberty Hyde Bailey Professor Dr. Carl A. Batt. Dr. Batt's laboratory strives to provide advancements in basic scientific research that will have a direct impact on society at large. The lab's scientists also work with the community to promote scientific understanding of students of all ages. While at the Batt Lab, I developed strategies for biofunctionalization of carbon nanotubes, quantum dots, and magnetic nanoparticles, and explored their potential as imaging agents and therapeutics. Collaborators of the lab included Ludwig Cancer Research, Memorial Sloan Kettering Cancer Center, New York Presbyterian Hospital, the Cornell NanoScale Science & Technology Facility, and the Cornell Nanobiotechnology Center. While at Cornell Diego received several fellowships including the National Institutes of Health Fellowship Ruth L. Kirschstein National Research Service Award (2007-2010), the Cornell SAGE Fellowship (2005), the Sloan Fellowship (2004), and the Cornell Nanobiotechnology Center Fellowship (2004).